ALKEM Alkem Lab Q3 FY26 results (Oct–Dec 2025) and concall
Alkem Laboratories delivered a stable Q3 FY26, marked by 10.7% YoY revenue growth, primarily driven by strong international sales and adjusted double-digit domestic growth. A significant strategic move was the acquisition of a 55% stake in MedTech company Occlutech, aiming for substantial revenue and margin expansion in the coming years. While the generic business faced headwinds, the company's chronic and prescription segments performed strongly, and it addressed an exceptional item related to Labour Codes.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 10.8%, net profit up 1.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 +17% | 3,737 +11% |
| EBITDA | 753 | 759 | 391 | 739 | 921 +22% | 828 +9% |
| Net profit | 702 | 641 | 322 | 668 | 779 +11% | 653 +2% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
